Research Analysts Offer Predictions for BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Beam Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will post earnings per share of ($3.48) for the year. Cantor Fitzgerald currently has a “Hold” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.01). The firm had revenue of $14.30 million for the quarter, compared to the consensus estimate of $14.52 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company’s revenue was down 16.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.22) EPS.

Several other analysts have also recently weighed in on the stock. Leerink Partners upgraded shares of Beam Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $27.00 to $39.00 in a research note on Wednesday, November 6th. Scotiabank began coverage on Beam Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $24.00 price target on the stock. Sanford C. Bernstein raised shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 7th. Wedbush reaffirmed an “outperform” rating and set a $57.00 price target on shares of Beam Therapeutics in a report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Beam Therapeutics in a report on Monday, December 9th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Beam Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $47.67.

Beam Therapeutics Price Performance

Shares of NASDAQ BEAM opened at $26.13 on Thursday. The stock’s fifty day moving average price is $26.33 and its two-hundred day moving average price is $25.72. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -14.95 and a beta of 1.92. Beam Therapeutics has a one year low of $20.84 and a one year high of $49.50.

Insider Buying and Selling at Beam Therapeutics

In other Beam Therapeutics news, President Giuseppe Ciaramella sold 51,110 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $26.36, for a total value of $1,347,259.60. Following the completion of the sale, the president now directly owns 109,150 shares of the company’s stock, valued at approximately $2,877,194. This represents a 31.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the transaction, the insider now directly owns 102,968 shares in the company, valued at approximately $2,541,250.24. This represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Beam Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV raised its position in Beam Therapeutics by 103.2% in the fourth quarter. KBC Group NV now owns 4,143 shares of the company’s stock worth $103,000 after acquiring an additional 2,104 shares during the period. Blue Trust Inc. lifted its stake in Beam Therapeutics by 36.3% in the fourth quarter. Blue Trust Inc. now owns 4,274 shares of the company’s stock valued at $105,000 after purchasing an additional 1,139 shares during the last quarter. SG Americas Securities LLC increased its position in Beam Therapeutics by 19.4% in the fourth quarter. SG Americas Securities LLC now owns 12,118 shares of the company’s stock worth $301,000 after buying an additional 1,971 shares during the last quarter. Avanza Fonder AB bought a new position in Beam Therapeutics during the fourth quarter worth about $1,247,000. Finally, GAMMA Investing LLC increased its holdings in shares of Beam Therapeutics by 23.9% in the fourth quarter. GAMMA Investing LLC now owns 5,722 shares of the company’s stock worth $142,000 after purchasing an additional 1,102 shares during the period. 99.68% of the stock is owned by hedge funds and other institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.